Latest Conference Articles

October 8th 2016, 8:47pm

ESMO Congress: Breast Cancer

Postmenopausal women with hormone receptor-positive metastatic breast cancer had significant slowing of disease progression with the addition of the investigational cyclin-dependent kinase 4/6 inhibitor ribociclib to endocrine therapy.

October 8th 2016, 10:20am

ESMO Congress: Gynecologic Cancers

Maintenance therapy with niraparib reduced the risk of progression or death by 73% compared with placebo for patients with germline BRCA-positive platinum-sensitive, recurrent ovarian cancer.

October 8th 2016, 10:15am

ESMO Congress

Treatment with ipilimumab reduced the risk of death by 28% versus placebo in patients with high-risk stage III melanoma.

October 8th 2016, 12:09am

ESMO Congress: Breast Cancer

Antonio Llombart-Cussac, MD, PhD, medical oncologist, chairman, Medical Oncology Service, University Hospital Arnau de Vilanova in Valencia, Spain, discusses the CASCADE study, which assessed declines in treatment efficacy over time in patients with metastatic breast cancer, during an interview at the 2016 ESMO Congress.

October 8th 2016, 12:01am

ESMO Congress: Lung Cancer

Lars Bastholt, MD, clinical oncologist, Odense University Hospital, discusses the use of lenvatinib to treat patients with non-small cell lung cancer at the 2016 ESMO Congress.

October 7th 2016, 11:52pm

ESMO Congress: Gynecologic Cancers

The majority of heavily pretreated patients with high-grade ovarian cancer and germline or somatic BRCA mutations showed a durable response to rucaparib.

October 7th 2016, 10:53pm

ESMO Congress: Lung Cancer

Almost 40% of patients with resected early-stage non–small cell lung cancer had evidence of tumor regression following neoadjuvant treatment with nivolumab (Opdivo) in a preliminary clinical trial.

October 7th 2016, 10:37pm

ESMO Congress

Over one-fourth of patients with metastatic melanoma in Europe do not have access to groundbreaking therapies that could extend their lives.

October 4th 2016, 1:53am

NCCN Hematologic Malignancies Congress

Dr. George Somlo, MD, medical oncologist, City of Hope, discusses recent highlights in multiple myeloma.

October 3rd 2016, 11:36pm

NCCN Hematologic Malignancies Congress

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discuses which chronic lymphocytic leukemia patients may benefit from ibrutinib frontline therapy and questions that remain after the RESONATE-2 trial.

October 2nd 2016, 11:04pm

NCCN Hematologic Malignancies Congress

There have been 10 agents approved over the last 12 years for the treatment of patients with multiple myeloma, and pivotal data for each agent has supported rapid inclusion into the NCCN treatment algorithms.

October 2nd 2016, 10:08pm

NCCN Hematologic Malignancies Congress

The preferred primary therapy for patients with multiple myeloma is induction therapy with a triplet regimen followed by autologous stem cell transplantation, consolidation, and maintenance.

October 2nd 2016, 8:39pm

NCCN Hematologic Malignancies Congress

There has been some debate over what should be the standard frontline treatment for patients with chronic lymphocytic leukemia: ibrutinib or chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab.

October 2nd 2016, 3:36am

NCCN Hematologic Malignancies Congress

Thomas LeBlanc, MD, assistant professor of medicine, Duke Cancer Institute, discusses why it is important to include patients in the decision-making process for the treatment of hematologic malignancies.

October 2nd 2016, 2:39am

NCCN Hematologic Malignancies Congress

​Steven Coutre, MD, professor of medicine (hematology) at Stanford University Medical Center, discusses considerations when selecting between oral therapies like ibrutinib and chemoimmunotherapy for first-line treatment of chronic lymphocytic leukemia (CLL).

October 1st 2016, 10:30pm

NCCN Hematologic Malignancies Congress

Jessica K. Altman, MD, discussed the potential of agents poised to transform the landscape of acute myeloid leukemia.

October 1st 2016, 9:42pm

NCCN Hematologic Malignancies Congress

Ruben Mesa, MD, discussed the latest NCCN treatment guidelines for myelofibrosis and emerging treatments in the field.

October 1st 2016, 9:23pm

NCCN Hematologic Malignancies Congress

As generic imatinib enters the market, new questions focus on a renewed role for the agent in conjunction with second-generation TKIs.

October 1st 2016, 5:06am

NCCN Hematologic Malignancies Congress

​Jerald P. Radich, MD, clinical research division, Fred Hutchinson Cancer Research Center, discusses the impact of the approval of generic imatinib in chronic myelogenous leukemia (CML).

October 1st 2016, 3:47am

NCCN Hematologic Malignancies Congress

Ruben Mesa, MD chair, hematology Mayo Clinic, MPN, discusses the new National Comprehensive Cancer Network (NCCN) guidelines for myeloproliferative neoplasms (MPN). Ruben Mesa, MD chair, hematology Mayo Clinic, MPN, discusses the new National Comprehensive Cancer Network (NCCN) guidelines for myeloproliferative neoplasms (MPN).